生物化学与生物物理学报(英文版)(Acta Biochimica et Biophysica Sinica)

生物化学与生物物理学报(英文版)(Acta Biochimica et Biophysica Sinica) 知网目次万方目次

  • CSCD
  • 科核
基本信息
  • 主管单位:

    中国科学院

  • 主办单位:

    中国科学院分子细胞科学卓越创新中心(生物化学与细胞生物学研究所)

  • 国际刊号:

    1672-9145;EISSN1745-7270

  • 国内刊号:

    31-1940/Q

  • 学科分类:

    本科学报

  • 字数:

    10000-20000

  • 有无基金:

    /有基金 100.0%

  • 周期:

    CN外文-月刊

  • 特殊属性:

    第一批认定学术期刊

联系信息
  • 电话:

    021-54920956/54920955/54920954/54922862

  • 邮箱:

    abbs@sibs.ac.cn(官网邮箱)

  • 复合因子:

    1.201

  • 综合因子:

    0.775

  • 收录:

    知网目次,万方目次

  • 级别:

    CSCD,科核

期刊简介

《生物化学与生物物理学报(英文版)(Acta Biochimica et Biophysica Sinica)》期刊已被查看:

更新频次

低频栏目:

2007年06期文章-20.0%-期平均发文量10篇
2007年05期文章-20.0%-期平均发文量10篇
2007年04期文章-20.0%-期平均发文量10篇
2007年03期文章-20.0%-期平均发文量10篇
2007年02期文章-20.0%-期平均发文量10篇

单位占比

其他-100.0%

一作占比

/有基金-100.0%

投稿指南

1、投稿方式:在线投稿。

2、刊内网址:http://www.abbs.org.cn/

https://www.sciengine.com/abbs/

3、投稿系统:https://mc.manuscriptcentral.com/abbs

4、主办单位官网:

http://cemcs.cas.cn/xhqk/qk/actabiochimicaetbiophysicasinica/

(中国科学院分子细胞科学卓越创新中心(生物化学与细胞生物学研究所))

5、出刊日期:月刊,每月出版1期。

2022年9月5日星期一

《生物化学与生物物理学报(英文版)》投稿须知

Acta Biochimica et Biophysica Sinica

Instructions to Authors

【官网信息】

Instructions to Authors

ABBS

is a scientific journal publishing monthly original articles, short

communications and review articles in Biochemistry, Molecular Biology

and Biophysics. Original articles and short communications should report

original work not published or considered for publication elsewhere.

Reviews should provide a concise introduction to the subject matter to

inform the readers of the latest developments in a certain area. ABBS

also publishes brief reports, such as “new phenomenon” which reports a

new finding, and “lab note” which reports an important preliminary

result or a novel useful method. In addition, ABBS publishes “research

highlight” which provides brief comments on a most recently published

work and discusses its impact on the future research.

Editorial Review and Acceptance

The

acceptance criteria for a manuscript are the quality and originality of

the research and its significance to our readership. Except where

otherwise stated, manuscripts are single-blind peer reviewed by at least

two anonymous reviewers and the editor. Final acceptance or rejection

rests with the Editorial Board, who reserves the right to refuse any

material for publication. To verify originality, your article may be

checked by the originality detection service Crossref Similarity Check.

Submission of Manuscripts

Manuscripts

should be written in readable English and must be submitted online

through our ScholarOne Manuscripts System. Once you have prepared your

manuscript according to the instructions please visit the online

submission website.

Initial

submission should include a cover letter (filling in the cover letter

section) stating that: (i) the content has not been published or

submitted for publication elsewhere, (ii) all authors are in agreement

with the content of the manuscript, and (iii) a brief CV of the

corresponding author. Authors must declare any financial support or

relationships that may pose conflict of interest. If tables or figures

have been reproduced from other sources, a letter from the copyright

holder (usually the Publisher) stating authorization to reproduce the

material must be attached to the covering letter.

The

final version of the accepted manuscript will be uploaded by the

editorial office after pre-editing (careful check of the main text and

figure quality suitable for type-setting and production). If too many

language problems are to be fixed during pre-editing, authors will be

contacted by the editors for the final approval.

If

you have difficulties in using the online submission system, please

feel free to contact the Editorial Office at the following address:

Editorial Office of Acta Biochimica et Biophysica Sinica

CAS Center for Excellence in Molecular Cell Science

Institute of Biochemistry and Cell Biology

320 Yueyang Road, Shanghai 200031, China

Tel: +86-21-54920956/54920955/54920954/54922862

Fax: +86-21-54920954

E-mail: abbs@sibs.ac.cn

Abbreviations

Abbreviations

should be used sparingly: only where they ease the reader's task by

reducing repetition of long, technical terms. Initially use the word in

full, followed by the abbreviation in parentheses. Thereafter use the

abbreviation only.

Genetic

nomenclature Standard genetic nomenclature should be used. For further

information, including relevant websites, authors should refer to the

genetic nomenclature guide in Trends in Genetics (Elsevier Science,

1998).

Nucleotide

sequence data can be submitted in electronic form to any of the three

major collaborative databases: DDBJ, EMBL or GenBank. It is only

necessary to submit to one database as data are exchanged between DDBJ,

EMBL and GenBank on a daily basis. The suggested wording for referring

to accession-number information is: 'These sequence data have been

submitted to the DDBJ/EMBL/GenBank databases under accession number

U12345.' Addresses are as follows:

DNA Data Bank of Japan (DDBJ)

EMBL Nucleotide Sequence Submissions

GenBank

Format of Manuscript

For

the correct format for the main document of submitted manuscripts,

authors are suggested to refer to Examples on this website.

Original

Articles should be arranged in the following order: (i) title,

author(s) and affiliation(s); (ii) running title; (iii) abstract and

keywords; (iv) introduction; (v) materials and methods; (vi) results;

(vii) discussion; (viii) acknowledgements; (ix) funding; (x) references;

(xi) figure and table legends; (xii) tables; (xiii) figures. Short

Communications should be arranged in the following order: (i) title,

author(s) and affiliation (s); (ii) running title; (iii) abstract and

keywords; (iv) introduction; (v) materials and methods; (vi) results and

discussion; (vii) acknowledgements; (viii) funding; (ix) references;

(x) figure and table legends; (xi) tables; (xii) figures. Lab Note and

New Phenomenon should be arranged in the following order: (i) title,

author(s) and affiliation(s); (ii) running title; (iii) main contents;

(iv) acknowledgements; (v) funding; (vi) references; (vii) figure and

table legends. The locations of figures and tables in the text should be

indicated. Footnotes to the text are not allowed and any such material

should be incorporated into the text as parenthetical matter.

Title:

The title should be short and informative, less than 20 words, and

should not include non-standard acronyms or abbreviations.

Authors

and affiliations: (i) the full names of all authors; (ii) the addresses

of the institutions at which the work was carried out together with the

full postal address including post codes; (iii) the email address,

telephone and facsimile numbers of the author to whom correspondence

about the manuscript should be sent. The present address of any author,

if different from that where the work was carried out, can be supplied

as a footnote.

Running title: A running title should be provided and should be less than 60 characters.

Abstract:

The abstract should describe clearly the aim, major findings and

conclusions of the research. It must not exceed 250 words.

Keywords:

Five or fewer key words should be listed below the abstract in

alphabetical order. Keywords should be taken from those recommended by

the Index Medicus Medical Subject Headings (MeSH) browser list at

http://www.nlm.nih.gov/mesh/meshhome.html

Introduction:

The basic principles of research, background, earlier related work and

the purpose of the present studies should be described in the

introduction.

Materials

and Methods: Experimental procedures should be brief but complete

enough to be repeated; procedures published previously should be cited

in references. Source of materials, including Company name, City, and

Country should be given in bracket where they first appear.

Results: It is recommended that results be presented in figures and tables along with a suitable description in the text.

Discussion: The discussion should be concise (no more than three pages) and focus on the interpretation of the results.

References:

The Vancouver system of referencing should be used (examples are given

below). In the text, references should be marked using [Arabic numerals]

in the order in which they appear.

In

the reference list, if a reference has many authors, list only the

first seven authors, followed by 'et al'. Reference to unpublished data

and personal communications should not appear in the list but should be

cited in the text only (e.g. Smith A, 2000, unpublished data). All

citations mentioned in the text, tables or figures must be listed in the

reference list.

Names

of journals should be abbreviated according to the style used in Index

Medicus. Authors are responsible for the accuracy of the references.

Neufeld

EB, Remaley AT, Demosky SJ, Stonik JA, Cooney AM, Comly M, Dwyer NK, et

al. Cellular localization and trafficking of the human ABCA1

transporter. J Biol Chem 2001, 276: 27584-27590.

Hanahan

D, Jessee J, Bloom FR. Techniques for transformation of E. coli. In:

Glover DM, Hames BD eds. DNA Cloning: A Practical Approach. 2nd ed.

England: Oxford University Press 1998, 122-123.

Footnotes:

A footnote below the key words can only include the present address(es)

of any author(s) if different from that in the affiliation(s).

Tables:

Tables should be self-contained and complement, but not duplicate,

information contained in the text. Tables should be consecutively

numbered in the text in Arabic numerals. Legends should be concise but

comprehensive: the table, legend and footnotes must be understandable

without reference to the text. Vertical grid lines should not be used to

separate columns. Each column in a table must have a heading, with

units of measurement in parentheses; all abbreviations must be defined

in footnotes.

……

更多详情:

https://www.sciengine.com/ABBS/authorCenter?scroll=section_1

中国全科医学发文选摘

  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析
  • 1、2019.V1版《NCCN结直肠癌诊治指南》更新要点解析

常见问题

  • 哪些期刊可以用来评职称?

    1、期刊要具备正规性和合法性,需在国家新闻出版总署备案,具备国内刊号(cn)。2、期刊要具备学术性,例如该期刊需被国内主流学术、数据库收录,例如被知网,万方,维普收录。具体详情可以咨询我们的客服老师为您解答。

  • 你们的服务可以保证文章被发表吗?

    期刊发表的成功与否,主要取决于文章内容的质量。期刊编辑会根据研究领域、创新性等多因素进行考量。我们会帮助您理解期刊的发表要求,助力提升发表几率,从而增加发表的机会。

  • 请问发表一篇期刊的费用是多少?

    期刊的种类繁多,其费用也各不相同。根据您的需求,将为您推荐最具性价比的期刊,让您能更便捷地找到心仪的期刊。一般来说,只要符合职称评定要求的,大多数作者都会选择性价比最高的期刊作为首选目标。

  • 如果发表不成功可以退款吗?

    如果因为我方原因导致未能发表成功,我们将全额退还相关费用。需要明确的是,稿件能否发表主要取决于期刊的独立考量。为了提升您的发表几率,我们会提供专业的指导和支持,帮助您避免拒稿,并助力提高您的稿件质量。

  • 请问文章发表需要多长时间?

    不同级别的期刊发表时间是不一样的。无论是普刊还是核心期刊,建议您提前准备。普刊需提前3-6个月,而核心期刊需提前一年左右。为确保职称评定流程顺利进行,建议您提前半年到一年进行准备,以免错过申请的最佳时机。

  • 期刊发表能加急见刊吗?

    为了确保顺利发表,建议您提前一些时间进行安排。本站仅提供投稿发表咨询服务,需要用户自己向出版商投稿且没有绿色通道,是否录用一切以出版商通知为准。